Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambien CR Paragraph IV Certification Filed

This article was originally published in The Pink Sheet Daily

Executive Summary

The first ANDA with a Paragraph IV certification for Ambien CR was submitted Jan. 19, according to FDA's certifications list, which was updated March 17

You may also be interested in...



Sanofi Suit Triggers 30-Month Stay Of FDA Action On Barr’s Ambien CR ANDA

Sanofi-Aventis filed a patent infringement suit against Barr on April 5 over the controlled release form of zolpidem.

Sanofi Suit Triggers 30-Month Stay Of FDA Action On Barr’s Ambien CR ANDA

Sanofi-Aventis filed a patent infringement suit against Barr on April 5 over the controlled release form of zolpidem.

Ambien CR, Razadyne ER Paragraph IV Certifications Filed

The first ANDA with a Paragraph IV certification for Sanofi-Aventis' sleep aid Ambien CR 6.25 mg was filed Feb. 24, according to FDA's May 16 updated list of filings

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel